Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLX475 + pembrolizumab in advanced gastric cancer
NCT04768686Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivumecirnon in gastric cancer (GC), sponsored by Hanmi Pharmaceutical. Started May 2021; status: completed.
02
Drugs
tivumecirnon
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04768686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768686.